We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NMIH:NASDAQNMI Holdings Inc Analysis

Data as of 2026-07-10 - not real-time

$41.16

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

NMI Holdings is trading at $41.16, comfortably above its 20‑day and 50‑day SMAs of $39.51 and $38.19, indicating short‑term momentum. However, the RSI of 69.4 places the stock in overbought territory, suggesting a potential pull‑back toward the identified resistance of $42.03. The MACD remains bullish with a positive histogram of 0.13, and volume is on an increasing trend, providing some support for the upside. The company is set to release its Q2 results on July 30, which could act as a catalyst for price movement. With a 30‑day volatility of 18.7 % and a low beta of 0.24, price swings are expected to be modest relative to the broader market.
Fundamentally, NMIH exhibits exceptionally high profitability, posting a gross margin of 76 %, operating margin of 72 % and a profit margin of 54 %. Revenue is growing at 5.9 % YoY while the trailing PE of 8.37 is well below the industry average of 17.64, signaling a value opportunity. The discounted cash‑flow model values the firm at roughly $65 per share, implying an upside of more than 50 % versus the current price and a modest analyst‑derived upside of 12 %. The balance sheet shows ample liquidity with $96 M in cash against a debt‑to‑equity ratio of 16.2, and free cash flow of $313 M supports ongoing operations. While the company carries no dividend, its strong cash generation and low leverage reduce dividend‑related concerns. Overall risk is tempered by the specialty‑insurance niche’s regulatory environment and a modest max drawdown of ‑15 %. Given the blend of solid fundamentals, attractive valuation and limited downside, the stock presents a compelling buy case for medium‑ and long‑term horizons, with a cautious hold stance in the near term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Overbought RSI suggests limited upside
  • Approaching resistance at $42.03
  • Upcoming Q2 earnings could trigger volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF indicates ~50% discount to intrinsic value
  • Strong profit margins and cash flow
  • Low beta and modest volatility support steady appreciation

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable earnings growth and high ROE
  • Specialty mortgage guaranty niche with barriers to entry
  • Undervalued relative to peers and DCF fair value

Key Metrics & Analysis

Financial Health

Revenue Growth5.90%
Profit Margin53.82%
P/E Ratio8.4
ROE15.57%
ROA8.86%
Debt/Equity16.17
P/B Ratio1.2
Op. Cash Flow$434.2M
Free Cash Flow$313.0M
Industry P/E17.6

Technical Analysis

TrendNeutral
RSI69.4
Support$36.53
Resistance$42.03
MA 20$39.51
MA 50$38.19
MA 200$38.37
MACDBullish
VolumeIncreasing
Fear & Greed Index94.59

Valuation

Fair Value$64.97
Target Price$46.17
Upside/Downside12.16%
GradeUndervalued
TypeValue

Risk Assessment

Beta0.24
Volatility18.68%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.